Download File - JOHN J. HADDAD, Ph.D.

Factoring in Antigen Processing in Designing Antitumor T-Cell Vaccines 21
expressed and produce immunogenic epitopes. Unfortunately, as with the other
class of antigens, the expression frequency of these genes is extremely variable,
both between patients and between cells within the same tumor lesion. In conclusion,
it appears that the ideal target remains to be identified. Nevertheless,
several potentially promising targets fulfilling the conditions listed above exist
and should be entering initial phases of clinical trials.
REFERENCES
1. Hickman HD, Luis AD, Buchli R, et al. Toward a definition of self: proteomic
evaluation of the class I peptide repertoire. J Immunol 2004; 172:2944–2952.
2. Barnea E, Beer I, Patoka R, et al. Analysis of endogenous peptides bound by soluble
MHC class I molecules: a novel approach for identifying tumor-specific antigens.
Eur J Immunol 2002; 32:213–222.
3. Burrows SR, Rossjohn J, McCluskey J. Have we cut ourselves too short in mapping
CTL epitopes? Trends Immunol 2006; 27:11–16.
4. DeMartino GN, Slaughter CA. The proteasome, a novel protease regulated by multiple
mechanisms. J Biol Chem 1999; 274:22123–22126.
5. Guillaume B, Chapiro J, Stroobant V, et al. Proteasome types that are intermediate
between the standard proteasome and the immunoproteasome, 3rd Charité
Zeuthener See Workshop: the function of the proteasome system in MHC class I
antigen processing, Zeuthener See, 2007.
6. Murata S, Sasaki K, Kishimoto T, et al. Regulation of CD8 þ T cell development by
thymus-specific proteasomes. Science 2007; 316:1349–1353.
7. Früh K, Yang Y, Arnold D, et al. Alternative exon usage and processing of the
major histocompatibility complex-encoded proteasome subunits. J Biol Chem 1992;
267:22131–22140.
8. Yang Y, Waters J, Fruh K, et al. Proteasomes are regulated by interferon g:
implications for antigen processing. Proc Natl Acad Sci USA 1992; 89:4928–4932.
9. Hallermalm K, Seki K, Wei C, et al. Tumor necrosis factor-a induces coordinated
changes in major histocompatibility class I presentation pathway, resulting in increased
stability of class I complexes at the cell surface. Blood 2001; 98:1108–1115.
10. Shin E-C, Seifert U, Kato T, et al. Virus-induced type I IFN stimulates generation of
immunoproteasomes at the site of infection. J Clin Invest 2006; 116:3006–3014.
11. Tanaka K, Ichihara A. Half-life of proteasomes (multiprotease complexes) in rat
liver. Bioch Biophys Res Comm 1989; 159:1309–1315.
12. Nandi D, Woodward E, Ginsburg DB, et al. Intermediates in the formation of mouse
20S proteasomes: implications for the assembly of precursor b subunits. EMBO J
1997; 16:5363–5375.
13. Morel S, Lévy F, Burlet-Schiltz O, et al. Processing of some antigens by the
standard proteasome but not by the immunoproteasome results in poor presentation
by dendritic cells. Immunity 2000; 12:107–117.
14. Barton LF, Cruz M, Rangwala R, et al. Regulation of immunoproteasome subunit
expression in vivo following pathogenic fungal infection. J Immunol 2002;
169:3046–3052.
15. Niedermann G. Immunological functions of the proteasome. Curr Top Microbiol
Immunol 2002; 268:91–136.